Cassava Sciences, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
SAVA Nasdaq 2830 www.cassavasciences.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cassava Sciences, Inc.

Promising Penny Stocks To Consider In May 2025 - May 16th, 2025 6:09 pm
Cassava Reports Q1 2025 Financials Results, Provides Business Update - May 8th, 2025 12:00 pm
Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC - May 1st, 2025 11:30 am
Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development - Apr 21st, 2025 8:30 pm
Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a Turnaround - Apr 1st, 2025 1:35 pm
Is the Future Bleak for SAVA Stock Following Another Setback? - Mar 31st, 2025 2:00 pm
Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug - Mar 26th, 2025 7:49 pm
Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More - Mar 26th, 2025 2:02 pm
Cassava ends simufilam Alzheimer’s programme after second Phase III failure - Mar 26th, 2025 12:11 pm
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study - Mar 26th, 2025 11:43 am
Sector Update: Health Care Stocks Fall Late Afternoon - Mar 25th, 2025 7:53 pm
Cassava Drops 19% Pre-Market After Decision to End Alzheimer's Program - Mar 25th, 2025 3:36 pm
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data - Mar 25th, 2025 12:05 pm
Cassava Sciences (SAVA): One of the Best Short-Term Stocks to Buy Right Now - Mar 18th, 2025 8:33 am
Cassava Sciences (SAVA) Upgraded to Buy: What Does It Mean for the Stock? - Mar 7th, 2025 5:00 pm
H.C. Wainwright focused on what results from Cassava’s ReFocus-ALZ might reveal - Mar 5th, 2025 4:20 pm
Cassava Sciences Reports 2024 Financial Results and Provides Business Update - Mar 3rd, 2025 12:30 pm
Cassava Sciences Licenses Simufilam Method of Treatment Patent - Feb 27th, 2025 12:00 pm
Cassava Gears Up to Report Q4 Earnings: What's in the Cards? - Feb 21st, 2025 3:37 pm
Cassava Sciences Provides a Business Update - Jan 7th, 2025 9:30 pm